KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Quest Diagnostics (DGX) EBITDA Margin (2016 - 2026)

Quest Diagnostics' EBITDA Margin history spans 18 years, with the latest figure at 13.78% for Q1 2026.

  • On a quarterly basis, EBITDA Margin rose 74.0% to 13.78% in Q1 2026 year-over-year; TTM through Mar 2026 was 14.27%, a 56.0% increase, with the full-year FY2025 number at 14.1%, up 47.0% from a year prior.
  • EBITDA Margin hit 13.78% in Q1 2026 for Quest Diagnostics, roughly flat from 13.76% in the prior quarter.
  • Over the last five years, EBITDA Margin for DGX hit a ceiling of 19.65% in Q1 2022 and a floor of 5.79% in Q4 2022.
  • Historically, EBITDA Margin has averaged 13.9% across 5 years, with a median of 13.77% in 2024.
  • Biggest five-year swings in EBITDA Margin: tumbled -1375bps in 2022 and later soared 588bps in 2023.
  • Tracing DGX's EBITDA Margin over 5 years: stood at 5.79% in 2022, then soared by 102bps to 11.67% in 2023, then increased by 18bps to 13.77% in 2024, then fell by 0bps to 13.76% in 2025, then grew by 0bps to 13.78% in 2026.
  • Business Quant data shows EBITDA Margin for DGX at 13.78% in Q1 2026, 13.76% in Q4 2025, and 13.71% in Q3 2025.